LARKSPUR, Calif.--(BUSINESS WIRE)--Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through a potentially best-in-class, computationally evolved IL-2 human antibody, today announced the planned presentation of preclinical data on its lead investigational therapy, AU-007, at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting. The SITC meeting will run Nov. 10-14, 2021, in Washington D.C., as well as virtually.
“We believe in the potential of our initial clinical candidate, AU-007, as a novel cancer treatment that could meaningfully impact the lives of patients with its highly differentiated approach to harnessing the power of IL-2 to eradicate solid tumors,” said Aron Knickerbocker, Aulos Bioscience’s chief executive officer. “We look forward to presenting preclinical data at the SITC Annual Meeting and to initiating clinical testing in patients with cancer by year end.”
Abstract ID |
Poster Number and Title |
Presenting Author |
14867 |
704: The computationally designed human antibody, AU-007, mediates human immune activation by endogenous IL-2, while uniquely breaking the IL-2 auto-inhibitory loop and preventing Treg expansion |
Yanay Ofran, Ph.D. Biolojic Design and Aulos Bioscience |
The poster will be presented in the Poster Hall at the Walter E. Washington Convention Center in Washington, D.C. Saturday, Nov. 13, 2021. It will also be available as an ePoster on display on the SITC 2021 virtual meeting platform from 7 a.m. EST on Friday, Nov. 12, 2021, until the virtual meeting platform is closed on Jan. 9, 2022.
About AU-007
AU-007 is a computationally evolved, human IgG1 monoclonal antibody that is highly selective to the CD25-binding portion of IL-2. With a mechanism of action unlike any other IL-2 therapeutic in development, AU-007 leverages the body's own IL-2 to reinforce anti-tumor immune effects. This is achieved by preventing IL-2 secreted by T effector cells from binding to trimeric receptors on T regulatory cells while still allowing IL-2 to bind and expand effector cells. This prevents the negative feedback loop caused by other IL-2 based treatments and biases the immune system towards activation over suppression. AU-007 also prevents IL-2 from binding to trimeric receptors on vasculature and pulmonary endothelium, which may significantly reduce the vascular leak syndrome and pulmonary edema associated with high-dose IL-2 therapy.
About Aulos
Aulos Bioscience is an immuno-oncology company working to revolutionize cancer patient care through best-in-class IL-2 therapeutics that direct patients’ own immune systems towards killing tumor cells. Matching world-class machine learning from founder and partner Biolojic Design with an in-depth understanding of the immune system, Aulos’ initial clinical candidate, AU-007, is a computationally evolved human antibody that harnesses the power of IL-2 to induce tumor killing while limiting the immunosuppression and toxicities typically associated with this validated pathway. The company was founded by Biolojic Design and ATP with $40M in Series A funding from ATP and is led by pioneers in the field of artificial intelligence, antibody development and cancer immunotherapies. For more information, visit www.aulosbio.com.
